跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Can AI Discover New Drugs? A High-Level Overview

1Why Drug Discovery Is Hard, and Where AI Fits2How AI Learns From Molecules and Proteins3Finding and Validating a Biological Target4Designing Molecules: Generative AI and Virtual Screening5From Hit to Lead: Optimizing Properties With AI6What AI Still Cannot Do7Judging the Claims: Real Successes, Failures, and Open Questions
Why Drug Discovery Is Hard, and Where AI Fits

The Long Road From Target to Approval

1 / 4
Look at the stages stacked from top to bottom. Each one is a gate: the compound has to pass before it moves down. Notice that the first stage is not about molecules at all — it is about choosing which protein in the body to aim at. Everything below that choice inherits its risk. If the target turns out to be the wrong one, no amount of clever chemistry further down will rescue the program. That is why the order matters, and why we will keep returning to the target decision.
0:00 / 0:00

Drug discovery is not one activity but a sequence of stages, each with its own goal and its own way of failing. It begins with target selection: researchers decide which biological molecule in the body, usually a protein, they want to influence. A protein is a large folded molecule that carries out specific jobs in cells, and a drug target is the particular protein whose activity the future medicine is meant to change.

Once a target is chosen, the search for a hit begins. A hit is any molecule that shows some measurable effect on the target. Hits are then refined into leads, molecules with better potency (the strength of the effect) and better drug-like behavior. This refinement stage is called lead optimization.

Only then does the compound enter preclinical testing, where it is examined in cells and animals for safety and for how the body absorbs and clears it. If it survives, it moves into human testing, which runs in three phases: phase 1 checks safety in a small group, phase 2 looks for signs of effectiveness, and phase 3 compares the drug against existing treatment in a large population. If the results hold, the developer submits the compound for regulatory approval, and only after approval does it reach patients.

The important structural fact is that these stages are sequential and gated. A compound that fails at any gate is discarded, and the money and years already spent on it are not recovered.

参考资料

  1. [1]Drug discovery and development: a complex, lengthy and expensive processncbi.nlm.nih.gov
1 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion